{
    "organizations": [],
    "uuid": "43c84301578f059e3b985d07bd3fb0bc166f7a89",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novo-nordisk-fda-approves-update-t/brief-novo-nordisk-fda-approves-update-to-tresiba-label-to-include-devote-data-idUSFWN1R80OZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Novo Nordisk: FDA Approves Update to Tresiba Label to Include Devote data",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - Novo Nordisk:\n* U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED AN UPDATE TO US PRESCRIBING INFORMATION FOR TRESIBA (INSULIN DEGLUDEC) TO INCLUDE DATA FROM THE DEVOTE TRIAL​\n* ‍FOLLOWING INTERACTIONS WITH FDA, NOVO NORDISK HAS WITHDRAWN APPLICATIONS RELATED TO DATA FROM SWITCH TRIALS​\n* ‍”VERY PLEASED THAT FDA HAS APPROVED UPDATED LABEL FOR TRESIBA AS ONLY BASAL INSULIN TO BE LABELLED WITH A LOWER RATE OF SEVERE HYPOGLYCAEMIA COMPARED TO INSULIN GLARGINE U100,” SAYS CSO MADS KROGSGAARD THOMSEN​ Source text for Eikon: Further company coverage: (Copenhagen newsroom)\n ",
    "published": "2018-03-26T21:46:00.000+03:00",
    "crawled": "2018-03-27T12:08:55.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "novo",
        "nordisk",
        "food",
        "drug",
        "administration",
        "fda",
        "approved",
        "update",
        "u",
        "prescribing",
        "information",
        "tresiba",
        "insulin",
        "degludec",
        "include",
        "data",
        "devote",
        "interaction",
        "fda",
        "novo",
        "nordisk",
        "withdrawn",
        "application",
        "related",
        "data",
        "switch",
        "pleased",
        "fda",
        "approved",
        "updated",
        "label",
        "tresiba",
        "basal",
        "insulin",
        "labelled",
        "lower",
        "rate",
        "severe",
        "hypoglycaemia",
        "compared",
        "insulin",
        "glargine",
        "u100",
        "say",
        "cso",
        "mads",
        "krogsgaard",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "copenhagen",
        "newsroom"
    ]
}